Treatment of Eosinophilic Granulomatosis with Polyangiitis: A Review.

Abstract

Eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss syndrome) is a rare type of anti-neutrophil cytoplasm antibody-associated vasculitis. Nevertheless, eosinophilic granulomatosis with polyangiitis stands apart because it has features of vasculitis and eosinophilic disorders that require targeted therapies somewhat different from those used for other anti-neutrophil cytoplasm antibody-associated vasculitides. Considerable advances have been made in understanding the underlying pathophysiology of eosinophilic granulomatosis with polyangiitis that have highlighted the key role of eosinophils and opened new therapeutic opportunities. Its conventional treatment relies mainly on agents that decrease inflammation: corticosteroids and immunosuppressant adjunction for severe manifestations. New therapeutic approaches are needed for refractory disease, relapses and issues associated with corticosteroid dependence, especially for asthma manifestations. Drugs under evaluation mostly target eosinophils and B cells. Results of low-evidence-based trials suggested possible efficacies of biologicals: B-cell-blocking rituximab and anti-immunoglobulin E omalizumab. Recently, the first large-scale randomised controlled trial on eosinophilic granulomatosis with polyangiitis proved the efficacy of anti-interleukin-5 mepolizumab. That finding opens a new era in eosinophilic granulomatosis with polyangiitis management, with mepolizumab approval but also in future drug evaluations and trial designs for eosinophilic granulomatosis with polyangiitis. Additional studies are needed to determine which patients would benefit most from targeted therapies and achieve personalised treatment for patients with eosinophilic granulomatosis with polyangiitis. Herein, we review eosinophilic granulomatosis with polyangiitis characteristics and provide an overview of established and novel pharmacological agents.

• Authors: Loïc Raffray, Loïc Guillevin
• Journal: Drugs (Drugs) Vol. 78 Issue 8 Pg. 809-821 (Jun 2018) ISSN: 1179-1950 [Electronic] New Zealand
• PMID: 29766394 (Publication Type: Journal Article, Review)

Chemical References

• Adrenal Cortex Hormones
• Antibodies, Antineutrophil Cytoplasmic
• Antibodies, Monoclonal, Humanized
• Immunosuppressive Agents
• Omalizumab
• Rituximab
• mepolizumab

Topics

• Adrenal Cortex Hormones (therapeutic use)
• Antibodies, Antineutrophil Cytoplasmic (metabolism)
• Antibodies, Monoclonal, Humanized (therapeutic use)
• Churg-Strauss Syndrome (drug therapy, immunology)
• Eosinophils (pathology)
• Granulomatosis with Polyangiitis (drug therapy, immunology)
• Humans
• Immunosuppressive Agents (therapeutic use)
• Omalizumab (therapeutic use)
• Rituximab (therapeutic use)